Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10533056

Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

The Regents of the University of California · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10532096

Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10526414

Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to i

VACCINEX, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10525104

Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colo

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10525068

Anti-inflammatory properties of marine lipid compositions

AKER BIOMARINE ANTARCTIC AS · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10526403

Anti-activin A antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10519240

Anti-FGFR1c antibody-FGF21 fusion proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10517948

Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

The Board of Regents of the University of Texas System · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10513533

Tunicamycin related compounds with anti-bacterial activity

The United States of America, as represented by the Secretary of Agriculture · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10513557

Anti-ASIC1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10513558

Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10501538

Anti-LILRB antibodies and their use in detecting and treating cancer

The Board of Regents of the University of Texas System · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10493149

Stable anti-OSMR antibody formulation

Kiniksa Pharmaceuticals, GmbH · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10494444

Anti-CD38 antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10472425

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10466259

Synthetic antigen compositions for detecting anti-phosphatidylethanolamine antibodies

Northwestern University · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10456373

Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition bas

OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “NORMOFARM” · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10457745

Anti-complement C1s antibodies

Bioverativ USA Inc. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10450382

Anti-complement C1s antibodies

Bioverativ USA Inc. · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10450372

Anti-thyroglobulin T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10444237

Anti-pancreatic cancer monoclonal antibody and use thereof

NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10442864

Anti-Tie2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10442856

Methods of treating obesity with anti-ANGPTL8 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10441552

Anti-microbial composition comprising cannabinoids

AXIM BIOTECHNOLOGIES. INC. · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted